Zydus Lifesciences
Growth unavailable
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Consolidated, unaudited, with limited review; quarter values from the signed results statement
Reported revenue (₹ million, except EPS in ₹): 79,096
Read summary and comparison caveats
Zydus Lifesciences reported consolidated September-quarter revenue from operations of ₹79,096 million, compared with ₹61,232 million a year earlier. Net profit after non-controlling interests was ₹9,255 million versus the updated comparison of ₹12,609 million. Profit before tax was ₹12,617 million and included net exceptional income of ₹13 million. These figures retain the statement's million-rupee units.
- Figures are from the company-hosted 16-page signed statement dated 4 Nov 2026, read in full on 17 Nov. The consolidated table and exceptional-item notes were visually checked. This is unaudited information subject to limited review, not an audited quarter. Half-year and standalone figures are not mixed into the table.
- The filing uses INR million. Amounts here remain in ₹ million, not ₹ crore; ten million rupees equals one crore rupees. EPS is in rupees per share and is not annualised. Only the printed current-quarter and same-quarter-last-year values are shown; no growth rates are calculated.
- The ₹9,255 million net profit is after ₹22 million of non-controlling interests. The ₹9,277 million profit before those interests is a different measure. In the comparison quarter, non-controlling interests were negative ₹200 million, giving net profit after those interests of ₹12,609 million.
- Net exceptional income of ₹13 million comprises a ₹396 million provision for rain-related asset damage, offset by ₹376 million of insurance claims receivable and a ₹33 million reversal of severance provision at Assertio. The prior-year quarter had ₹342 million of exceptional expenses. These are the pre-tax items in Note 4, not an adjusted-PAT calculation.
- Note 13 says purchase-price-allocation finalisation for Amplitude updated prior-period net profit. The September 2025 comparator used here is ₹12,609 million, rather than the previously reported ₹12,586 million. The filing also updates the June 2026 comparator, which is not used here.
- Note 5 flags tax comparability: the parent recognised a ₹515 million deferred-tax remeasurement gain in the March 2026 quarter, and a subsidiary has MAT-credit adjustments in earlier periods. The filing states current-period tax expenses are not comparable with previous reported periods. Acquisitions also change group scope: results include Comfort Click from 29 Aug 2025, Amplitude from 29 Jul 2025, Agenus facilities from 15 Jan 2026 and Assertio from 16 Jun 2026; this is not a like-for-like organic-growth table.
- The limited-review report relies on other auditors for some subsidiaries and management-certified unreviewed information for others and joint ventures; it states its conclusion is not modified for those matters. The source document and notes remain necessary for the full context.
Checked 17 Nov 2026
Open original filing